NPHLA Daily — November 3, 2026

Good morning. Here is what changed across metabolic medicine, pharmacy regulation, aesthetics and healthcare technology since yesterday — every item linked to its source.

Top development today

What changed today in Metabolic: 8 trial updates

NPHLA tracked 8 new official records on this desk today: 8 trial updates. First: New trial registered: BOLD (Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity)

Metabolic signal

New trial registered: ERCG vs Intensive Lifestyle Intervention for Weight Regain After GLP-1 RA Discontinuation

Not applicable, Affiliated Hospital to Academy of Military Medical Sciences. Conditions: Obesity & Overweight. Interventions: Endoscopic Radial Compression Gastroplasty (ERCG); Intensive Lifestyle Intervention (ILI). Investigational:…

Aesthetics & Longevity signal

What changed today in Aesthetics & Longevity: 1 trial update

NPHLA tracked 1 new official record on this desk today: 1 trial update. First: Trial status changed to “Active, not recruiting”: A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of…

AI & Technology signal

What changed today in AI & Technology: 1 new study

NPHLA tracked 1 new official record on this desk today: 1 new study. First: New research in International journal of medical informatics: “Physician digital health literacy and generative AI for public health communication: a five-country comparative case study with a…

One thing worth watching

Comments close: Compounding Animal Drugs From Bulk Drug Substances: Compounding Under CGMP in Federally-Registered Facilities; Draft Guidance for Industry; Availability; Agency Information…

November 26, 2026 — verified from the Federal Register comments_close_on.

5 things to know

Compiled by NPHLA Intelligence from published briefings and official records. Professional information only — not medical or legal advice. Our standards.